Amicus Therapeutics (FOLD) Given New $24.00 Price Target at Leerink Swann

Amicus Therapeutics (NASDAQ:FOLD) had its price target upped by Leerink Swann from $20.00 to $24.00 in a report issued on Thursday. Leerink Swann currently has an outperform rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on FOLD. ValuEngine upgraded shares of Amicus Therapeutics from a sell rating to a hold rating in a report on Friday, February 2nd. Robert W. Baird set a $20.00 price objective on shares of Amicus Therapeutics and gave the stock a buy rating in a report on Wednesday. Zacks Investment Research upgraded shares of Amicus Therapeutics from a strong sell rating to a hold rating in a report on Wednesday, January 17th. BidaskClub upgraded shares of Amicus Therapeutics from a sell rating to a hold rating in a report on Thursday, December 21st. Finally, Cowen reiterated a buy rating and set a $22.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $19.06.

Amicus Therapeutics (FOLD) traded down $0.88 during trading on Thursday, hitting $13.99. 2,413,020 shares of the company’s stock traded hands, compared to its average volume of 3,163,026. Amicus Therapeutics has a one year low of $5.87 and a one year high of $17.40. The firm has a market cap of $2,806.63, a PE ratio of -7.60 and a beta of 1.46. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. Amicus Therapeutics’s revenue for the quarter was up 419.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.33) earnings per share. equities research analysts predict that Amicus Therapeutics will post -1.52 earnings per share for the current fiscal year.

In related news, insider Jay Barth sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $16.80, for a total value of $336,000.00. Following the transaction, the insider now owns 105,409 shares in the company, valued at $1,770,871.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John F. Crowley sold 65,581 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $13.51, for a total transaction of $885,999.31. Following the completion of the transaction, the chief executive officer now owns 393,076 shares in the company, valued at approximately $5,310,456.76. The disclosure for this sale can be found here. Insiders sold 250,390 shares of company stock worth $3,620,581 in the last 90 days. 3.40% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the business. Perceptive Advisors LLC grew its position in Amicus Therapeutics by 3.4% in the third quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock valued at $269,760,000 after acquiring an additional 591,925 shares in the last quarter. Jennison Associates LLC grew its position in Amicus Therapeutics by 9.4% in the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after acquiring an additional 838,267 shares in the last quarter. Vanguard Group Inc. grew its position in Amicus Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after acquiring an additional 430,486 shares in the last quarter. Janus Henderson Group PLC grew its position in Amicus Therapeutics by 5.8% in the third quarter. Janus Henderson Group PLC now owns 7,434,314 shares of the biopharmaceutical company’s stock valued at $112,109,000 after acquiring an additional 407,304 shares in the last quarter. Finally, State Street Corp grew its position in Amicus Therapeutics by 2.2% in the second quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after acquiring an additional 125,635 shares in the last quarter.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2018/02/09/amicus-therapeutics-fold-given-new-24-00-price-target-at-leerink-swann.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit